Literature DB >> 21111963

Metastasectomy for stage IV melanoma: for whom and how much?

Abigail S Caudle1, Merrick I Ross.   

Abstract

Although the conventional paradigm for treating metastatic melanoma relies on systemic therapies, a surgical approach should be strongly considered in selected patients. A surgical approach may not be appropriate for all patients, but it can offer a rapid clearance of disease without the toxicity of systemic therapy. Patient selection is of paramount importance for surgery to be effective. The rationale for surgical intervention in the management of metastatic melanoma, selection factors to be considered, published results, and future directions are discussed in this article.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21111963     DOI: 10.1016/j.soc.2010.09.010

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  11 in total

1.  A 20-year experience of hepatic resection for melanoma: is there an expanding role?

Authors:  Mark B Faries; Anna Leung; Donald L Morton; Danielle Hari; Ji-Hey Lee; Myung-shin Sim; Anton J Bilchik
Journal:  J Am Coll Surg       Date:  2014-05-10       Impact factor: 6.113

2.  Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis.

Authors:  Andrea Forschner; Susann-Cathrin Olthof; Brigitte Gückel; Peter Martus; Werner Vach; Christian la Fougère; Konstantin Nikolaou; Ulrike Keim; Thomas Kurt Eigentler; Claus Garbe; Christina Pfannenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-18       Impact factor: 9.236

Review 3.  Surgery for distant melanoma metastasis.

Authors:  Anna M Leung; Danielle M Hari; Donald L Morton
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

4.  Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.

Authors:  Susann-Cathrin Schüle; Thomas Kurt Eigentler; Claus Garbe; Christian la Fougère; Konstantin Nikolaou; Christina Pfannenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-18       Impact factor: 9.236

Review 5.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

6.  In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

Authors:  Narges K Tafreshi; Ariosto Silva; Veronica C Estrella; Timothy W McCardle; Tingan Chen; Yolaine Jeune-Smith; Mark C Lloyd; Steven A Enkemann; Keiran S M Smalley; Vernon K Sondak; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2013-07-08       Impact factor: 4.939

7.  Metastatic melanoma to the brain: surgery and radiation is still the standard of care.

Authors:  Sarah Nicholas; Dimitrios Mathios; Christopher Jackson; Michael Lim
Journal:  Curr Treat Options Oncol       Date:  2013-06

8.  Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Authors:  Narges K Tafreshi; Xuan Huang; Valerie E Moberg; Natalie M Barkey; Vernon K Sondak; Haibin Tian; David L Morse; Josef Vagner
Journal:  Bioconjug Chem       Date:  2012-11-27       Impact factor: 4.774

9.  Isolated rectus abdominis metastasis from melanoma-An extremely rare case.

Authors:  Alberto Gómez Portilla; Anais Cruz; Nuria Juan; Palmira Malo; Eduardo López de Heredia; Maitane Larrañaga
Journal:  Int J Surg Case Rep       Date:  2016-07-22

10.  Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.

Authors:  Nicholas D Klemen; Paul L Feingold; Stephanie L Goff; Marybeth S Hughes; Udai S Kammula; James C Yang; David S Schrump; Steven A Rosenberg; Richard M Sherry
Journal:  Ann Surg Oncol       Date:  2016-09-16       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.